MT2017-45 :CAR-T Cell Therapy for Heme Malignancies
0-9 years 10-17 years 18-26 years
Condition: Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately.